Biotech

At Applied DNA, they’re really getting into leather

By GREGORY ZELLER // A new international partnership backed by a host of well-known global brands will develop DNA-based security and product-authentication solutions for the leather industries. Stony Brook-based biotech Applied DNA Sciences this week announced a “research agreement” with BLC Leather Technology Centre, a UK-based R&D firm that delivers a range of services to leather suppliers, manufacturers and distributors in some 40 countries. Applied DNA President and CEO James Hayward was slated to officially…

Read More

Still cutting its teeth, Traverse set for stellar 2017

By GREGORY ZELLER // First, healthy teeth for dogs … then a cancer cure for the world? Financially and otherwise, Traverse Biosciences enjoyed a strong 2016 – but it may ultimately pale compared to what’s shaping up as a potentially enormous 2017 for the Stony Brook biotech and its flagship pharmaceutical. Fueled primarily by a $1.32 million Phase II Small Business Technology Transfer award granted by the National Institutes of Health in August to the…


Tackling concussions with cannabis

By GREGORY ZELLER // A research effort stretching from Florida to Long Island to Canada’s Alberta province will determine if compounds derived from marijuana can be effective treatments for concussions. Calgary-based R&D firm Scythian Biosciences has agreed to fund a University of Miami study, to be conducted by the university’s The Miami Project to Cure Paralysis and Miller School of Medicine, exploring cannabinoid-based methods of reducing post-concussion brain cell inflammation, which causes headaches and other neurological complications….


Codagenix, SUNY RF ink exclusive licensing deal

A year of big steps has led to one giant leap for Codagenix. Stony Brook University, through the Research Foundation for the State University of New York, has entered into an exclusive licensing agreement with the Farmingdale-based biotech to commercialize a platform technology aiming to create a “pipeline of live attenuated vaccines” against viral infections attacking humans and other animals. The exclusive licensing agreement, announced Wednesday, involves technology developed in the laboratory of Eckard Wimmer,…


In Brazil, a big forward step for Chembio

The national health-regulatory agency of Brazil has approved commercial use of Chembio Diagnostics’ rapid field rest for the Zika virus – a major step toward selling the product in the Zika-ravaged Brazilian market. Brazil’s Agência Nacional de Vigilância Sanitária (ANVISA) has greenlighted the DPP Zika IgM/IgG Assay, which detects antibodies using a tiny drop of blood and provides “semi-quantitative results” in 15 minutes, according to the company, using Chembio Diagnostics’ patented virus-detection platform and a…


Codagenix commences Zika vaccine testing

By GREGORY ZELLER // Farmingdale biotech Codagenix Inc. has commenced the first tests of its potential Zika virus vaccines in a living host. In a noteworthy display of speed sure to impress the medical community and potential investors alike, the 2012 startup began in vivo testing of its live-attenuated Zika virus vaccine candidates earlier this month – just 27 days after it plugged Zika into its proprietary, synthetic biology-based vaccine-design platform. The safety and efficacy study…


Chembio lands $13.2M Zika contract

Medford-based Chembio Diagnostics has won a $13.2 million federal contract to further develop its rapid test for the Zika virus, the company announced Thursday. Almost $6 million of the money – from the Department of Health and Human Services – will go toward its Zika test and a companion field monitor, the company said. Another $7.3 million will be used for development of a combination test for Zika, chikungunya and dengue. The firm, which also makes…